These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11192828)

  • 1. Monitoring therapy by serum HER-2/neu.
    Schwartz MK; Smith C; Schwartz DC; Dnistrian A; Neiman I
    Int J Biol Markers; 2000; 15(4):324-9. PubMed ID: 11192828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course.
    Schöndorf T; Hoopmann M; Warm M; Neumann R; Thomas A; Göhring UJ; Eisberg C; Mallmann P
    Clin Chem; 2002 Aug; 48(8):1360-2. PubMed ID: 12142395
    [No Abstract]   [Full Text] [Related]  

  • 3. HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study.
    Hoopmann M; Neumann R; Tanasale T; Schöndorf T
    Anticancer Res; 2003; 23(2A):1031-4. PubMed ID: 12820343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer.
    Cook GB; Neaman IE; Goldblatt JL; Cambetas DR; Hussain M; Lüftner D; Yeung KK; Chan DW; Schwartz MK; Allard WJ
    Anticancer Res; 2001; 21(2B):1465-70. PubMed ID: 11396233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer.
    Lüftner D; Cheli C; Mickelson K; Sampson E; Possinger K
    Int J Biol Markers; 2004; 19(3):175-82. PubMed ID: 15503818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
    Ali SM; Carney WP; Esteva FJ; Fornier M; Harris L; Köstler WJ; Lotz JP; Luftner D; Pichon MF; Lipton A;
    Cancer; 2008 Sep; 113(6):1294-301. PubMed ID: 18661530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients.
    Bethune-Volters A; Labroquere M; Guepratte S; Hacene K; Neumann R; Carney W; Pichon MF
    Anticancer Res; 2004; 24(2C):1083-9. PubMed ID: 15154627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated assay for HER-2/neu in serum.
    Payne RC; Allard JW; Anderson-Mauser L; Humphreys JD; Tenney DY; Morris DL
    Clin Chem; 2000 Feb; 46(2):175-82. PubMed ID: 10657373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
    Carney WP
    IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method.
    Kuroda N; Kontani K; Kajikawa T; Taminato T
    Rinsho Byori; 2010 Jun; 58(6):541-52. PubMed ID: 20662264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].
    Couto Mdo R; Pinto D; Oliveira J; Monteiro A; Pereira D; Medeiros R; Rodrigues H
    Acta Med Port; 2011; 24(1):5-16. PubMed ID: 21672436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
    Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.
    Hudelist G; Köstler WJ; Attems J; Czerwenka K; Müller R; Manavi M; Steger GG; Kubista E; Zielinski CC; Singer CF
    Br J Cancer; 2003 Sep; 89(6):983-91. PubMed ID: 12966413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu gene product in serum--an oncoprotein in the diagnosis and therapy of breast carcinoma.
    Schulze G
    Anticancer Res; 2003; 23(2A):1007-10. PubMed ID: 12820339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue expression and serum levels of HER-2/neu in patients with breast cancer.
    Krainer M; Brodowicz T; Zeillinger R; Wiltschke C; Scholten C; Seifert M; Kubista E; Zielinski CC
    Oncology; 1997; 54(6):475-81. PubMed ID: 9394844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
    Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
    Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.